

Underpinning Science: State of the Art Non-Cancer Effects, Especially **Circulatory Diseases** Mark P. Little **Radiation Epidemiology Branch National Cancer Institute** IRPA 13 Scottish Exhibition and Conference Centre Glasgow 13-18 May 2012



Outline of talk

Introduction

- □ Circulatory disease
 - A-bomb survivors, occupationally-exposed cohorts
 - Meta-analysis of circulatory disease in moderate+low-dose epidemiological data

□ Cataract

- Other non-malignant endpoints
 - Respiratory, digestive
 - □ Neuro-cognitive
- Conclusions

Dose response for circulatory disease in A-bomb survivors (Shimizu et al. Br. Med. J. 340:b5349;2010)



Fig 1| Radiation dose-response relation (excess relative risk per Gy) for death from stroke, showing linear and linearquadratic functions. Shaded area is 95% confidence region for fitted linear line. Vertical lines are 95% confidence intervals for specific dose category risks. Point estimates of risk for each dose category are indicated by circles

ERR/Sv heart (ICD9 393-400,402,404,406-429)

ERR/Sv stroke (ICD9 430-438)



NOTE - TOWARDS A NEW PARADIO

Fig 2 | Radiation dose-response relation (excess relative risk) for death from heart disease, showing linear and linearquadratic functions. Shaded area is 95% confidence region for fitted linear line. Vertical lines are 95% confidence intervals for specific dose category risks. Point estimates of risk for each dose category are indicated by circles

0.18 (95% CI 0.11, 0.25)

0.12 (95% CI 0.05, 0.19)

ERR/Sv other circulatory (ICD9 393-459 - above) 0.58 (95% CI 0.45, 0.72) Significant dose response, but excess risk only clear above ~0.5 Gy

Dose response same if adjusted for smoking, drinking + other CVD risk factors

Shape of dose-response uncertain: weak indications (linear-quadratic vs linear p=0.17) of upward curvature for stroke, none (p>0.5) for heart disease

Dose response for ischemic heart disease +stroke morbidity in Mayak nuclear

Workers (Azizova et al. Radiat. Res. 174:155-68; 2010, Radiat. Res. 174:851-64; 2010)



ERR/Gy ischemic heart (ICD9 410-414) 0.119 (95% CI 0.051, 0.186)

ERR/Gy cerebrovascular (ICD9 430-438) 0.449 (95% CI 0.338, 0.559)

Adjustment for smoking and drinking makes almost no difference

VATIONAL CANCER STITUTE

Circulatory excess relative risk Sv⁻¹ in occupational groups (Little *et al. Radiat. Res.* 169:99-109;2008, Little *et al. Radiat.*

Env. Biophys. 49:139-153;2010, Little et al. Env. Health Perspect. 2012 in press)` Chernobyl recovery hypertension 0.26 (95% CI -0.04 -0.56) 0.41 (95% CI 0.05 - 0.78)Chernobyl recovery ischaemia heart Chernobyl recovery other heart -0.26 (95% CI -0.81 - 0.28) 0.45 (95% CI 0.11 - 0.80) Chernobyl recovery stroke Mayak ischaemic heart (external γ) 0.11 (95% CI 0.05 - 0.17) 0.46 (95% CI 0.36 - 0.57) Mayak stroke (external γ) $0.25 \quad (95\% \text{ CI} - 0.01 - 0.54)$ NRRW-3 circulatory BNFL circulatory 0.54 (90% CI 0.30 - 0.82) **BNFL** ischaemic heart 0.70 (90% CI 0.37 - 1.07) 0.66 (90% CI 0.17 - 1.27) **BNFL** stroke (90% CI -2.9 -13.7) EdF ischemic heart 4.1 17.4 (90% CI 0.2 – 43.9) EdF stroke Canadian uranium workers ischaemic heart 0.15 (95% CI -0.14 - 0.58) -0.29 (95% CI < -0.29 - 0.27)Canadian uranium workers stroke -2.86 (95% CI -6.90 – 1.18) US Oak Ridge ischaemic heart German uranium miner circulatory -0.26 (95% CI -0.6 -0.05)

Increased risk in Chernobyl, Mayak, NRRW-3, BNFL, EdF (?) Most other risks negative, consistent with modest excess risk



Meta analysis of circulatory disease (Little *et al. Env. Health Perspect.* 2012 in press)`

PubMed + ISI Thompson search using terms "radiation" +"heart" +"disease" or "radiation" +"stroke" or "radiation" +"circulatory" +"disease", published $\geq 1/1/1990$ (search on 14/5/2011 + 17/8/2011)

Restricted to human data exposed to moderate/low uniform whole body doses (acute mean dose <0.5 Sv – limit suggested by radiobiology, but chronic exposures allowed higher), with good quality dosimetry

12 studies identified

Fixed effect + random effects analysis (random effects needed when significant heterogeneity)



Problems with meta-analysis:

publication/selection bias?

- Generally expect bias towards publications with significant results
- Funnel plot (mean vs SE) is reasonably symmetric, implying little or no bias (possible slight problem with Laurent et al., but little information in this study) All data



Test of publication/selection bias,

and bias correction (Little et al. Env. Health Perspect. 2012 in press)

Disease endpoint	Egger et al.	Random effects ERR	Random effects ERR	
	publication/selection-	Sv ⁻¹ (and 95% CI),	Sv ⁻¹ (and 95% CI),	
	bias test <i>p</i> -value	bias-uncorrected	corrected using trim-	
			and-fill method of	
			Duval and Tweedie	
Ischaemic heart disease	0.322	0.10 (0.04, 0.15)	0.09 (0.02, 0.15)	
Other heart disease	0.468	0.08 (-0.12, 0.28)	0.08 (-0.12, 0.28)	
Cerebrovascular disease	0.692	0.21 (0.02, 0.39)	0.20 (0.02, 0.39)	
Other circulatory disease	0.408	0.19 (-0.00, 0.38)	0.16 (-0.03, 0.35)	
All circulatory disease	0.279	0.11 (0.03, 0.19)	0.16 (0.08, 0.24)	

Little evidence of publication/selection bias, and bias corrections are minimal



Confounding factors for circulatory disease

Few studies adequately control for established circulatory risk factors (smoking, diabetes, obesity/inactivity, hypertension, low HDL/high LDL cholesterol)

- A-bomb morbidity study (Yamada et al Radiat Res 161:622-32;2004) controls for smoking, drinking
- A-bomb circulatory mortality adjusted for smoking, alcohol intake, education, occupation, obesity (BMI), diabetes mellitus (Shimizu *et al Br Med J* 340:b5349;2010)
- Mayak study (Azizova et al Radiat Res 174:155-68,851-64;2010) controls for smoking and drinking

Many of these risk factors correlated with socioeconomic status (SES): limited adjustment for SES in some occupational studies (IARC 15country, BNFL, NRRW-3), none in others

Will they confound (i.e., are they correlated with radiation dose)?

- No evidence for confounding by these in A-bomb or Mayak studies
- Lack of associations between radiation dose and smoking-related nonmalignant respiratory diseases in occupational studies (IARC 15-country, NRRW-3, EdF) implies that smoking unlikely to confound in these cohorts



Meta-analysis of moderate/low dose circulatory disease: excess relative risk coefficients (Little et al. Env. Health

Perspect. 2012 in press)

		Fixed-effect	Random-effect	
Circulatory disease		ERR / Sv	ERR / Sv	
subtype	Studies Included	(+95% CI)	(+95% CI)	Heterogeneity p
Ischemic heart	Yamada et al., Ivanov et	0.10	0.10	0.408
disease	al., Vrijheid et al.	(0.05 to 0.15)	(0.04 to 0.15)	
	Muirhead et al. Azizova et			
	al., Shimizu et al., Laurent			
	et al., Lane et al.			
Non-ischemic heart	Ivanov et al., Vrijheid et	0.12	0.08	0.199
disease	al., Shimizu et al.	(-0.01 to 0.25)	(-0.12 to 0.28)	
Cerebrovascular	Yamada et al., Ivanov et	0.20	0.21	< 0.001
disease	al., Kreuzer et al.,	(0.14 to 0.25)	(0.02 to 0.39)	
	Vrijheid et al., Azizova et			
	al., Muirhead et al.,			
	Shimizu et al., Laurent et			
	al., Lane et al.			
Circulatory disease	Yamada et al., Ivanov et	0.10	0.19	< 0.001
apart from heart	al., Shimizu et al.	(0.05 to 0.14)	(-0.00 to 0.38)	
disease and stroke				



 Random effects model suggests significant excess risk for ischaemic heart disease and stroke
Rondorling significant excess risk for girculatory disease apart from heart

Borderline significant excess risk for circulatory disease apart from heart and stroke



Radiation-Exposure-Induced Death for Various Subtypes of Circulatory Disease, by Country (Little

et al. Env. Health Perspect. 2012 in press)

				Other	All	UNSCEAR ca	ancer risks
Country	Ischaemic	Other heart		circulatory	circulatory	All solid	Leukemia
	heart disease	disease	Stroke	disease	disease	cancer	excl CLL
China	0.92 (0.41, 1.42)	0.11 (-0.16, 0.37)	4.31 (0.48, 8.14)	1.43 (-0.01, 2.86)	6.76 (2.63, 10.89)	3.95 3.89	0.27 0.42
France	0.50 (0.22, 0.78)	0.54 (-0.85, 1.94)	0.92 (0.10, 1.74)	0.53 (0.00, 1.05)	2.50 (0.77, 4.22)	-	-
Germany	1.71 (0.76, 2.65)	0.97 (-1.52, 3.46)	1.69 (0.19, 3.19)	1.38 (-0.01, 2.76)	5.75 (2.39, 9.10)	-	-
Japan	0.57 (0.25, 0.88)	0.80 (-1.25, 2.85)	2.19 (0.24, 4.14)	0.45 (0.00, 0.91)	4.01 (1.13, 6.89)	4.65 4.90	0.32 0.43
Russia	2.82 (1.26, 4.39)	0.31 (-0.49, 1.11)	4.59 (0.51, 8.66)	0.79 (0.00, 1.57)	8.51 (4.00, 13.02)	-	-
Spain	0.91 (0.41, 1.42)	0.82 (-1.28, 2.52)	1.91 (0.21, 3.60)	0.81 (0.00, 1.63)	4.45 (1.73, 7.17)	Circulator	ry disease
Ukraine	4.14 (1.85, 6.43)	0.20 (-0.31, 0.70)	2.85 (0.31, 5.39)	0.93 (0.00, 1.85)	8.11 (4.53, 11.69)	with cance	arable er risk
UK	1.70 (0.76, 2.64)	0.37 (-0.58, 1.32)	2.24 (0.25, 4.22)	0.76 (0.00, 1.53)	5.07 (2.55, 7.58)	5.15 4.40	0.38 0.43
USA	1.82 (0.81, 2.82)	0.57 (-0.89, 2.03)	1.29 (0.14, 2.44)	0.80 (0.00, 1.61)	4.48 (2.22, 6.74)	4.74 4.41	0.47 0.42



Significant increase in cortical and PSC, but nothing significant for nuclear color or opacity



Cataract in A-bomb survivors: (surgical removal) (Neriishi et al. Radiat. Res. 168:404-8; 2007)



Median cortical opacity ratio (exposed vs unexposed) in NASA astronauts (LOCS III)(Chylack *et al. Radiat. Res.* 172:10-20; 2009)



Significant (p=0.017) increase in cortical opacity (parameter σ in skew normal) exposed *vs* unexposed astronauts

No assessment of dose response in this cohort



Threshold dose estimates for cataract

Cohort	Ascertainment	Threshold dose estim	ates (Gy)
A-bomb AHS examination (Nakashima et al. Health Phys. 90 :154-60; 2006)	LOCS II	Cortical: PSC:	0.6 (90% CI <0, 1.2) 0.7 (90% CI <0, 2.8)
A-bomb AHS cataract surgery (Neriishi <i>et al.</i> <i>Radiat. Res.</i> 168 :404-8; 2007)	Surgical removal	All cataract:	0.1 (95% CI <0, 0.8)
Chernobyl recovery worker (Worgul <i>et al.</i> <i>Radiat. Res.</i> 167 :233-43; 2007)	Merriam-Focht	Non-nuclear stage 1: PSC stage 1: All cataract stage 1-5:	0.50 (95% CI 0.17, 0.69) 0.35 (95% CI 0.19, 0.66) 0.50 (95% CI 0.17, 0.65)

Thresholds of much more than 0.6 Gy are inconsistent with A-bomb + Chernobyl data



Cataract summary risk estimates

Cohort	Ascertain -ment	Endpoint Exces	ss odds ratio (EOR) / Gy (95% CI)
Swedish skin haemangioma (Hall et al Radiat Res 152:190-5; 1999)	LOCS I	Cortical: PSC:	0.50 (0.15, 0.95) 0.49 (0.07, 1.08)
A-bomb AHS (Nakashima et al Health Phys 90:154-60; 2006)	LOCS II	Cortical (/Sv): PSC (/Sv): Nuclear opacity (/Sv):	0.30 (0.10, 0.53) 0.44 (0.19, 0.73) 0.07 (-0.11, 0.30)
A-bomb AHS cataract surgery (Neriishi et al Radiat Res 168:404-8; 2007)	Surgical removal	All cataract removal:	0.39 (0.24, 0.55)
Icelandic airline pilots (Rafnsson <i>et al Arch Opthalmol</i> 123:1102-5; 2005)	WHO	Nuclear: Cortical: PSC:	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$
Chernobyl recovery worker (Worgul <i>et al Radiat Res</i> 167:233-43; 2007)	Merriam- Focht	Non-nuclear stage 1-5: Nuclear: All cataract stage 1-5:	0.65 (0.18, 1.30) 0.07 (-0.44, 1.04) 0.70 (0.22, 1.38)
US Radiologic technologist (Chodick <i>et al Am J Epidemiol</i> 168 :620-31; 2008)	Self- reported removal	All cataract removal: Endpoint heteroge	2.0 (-0.7, 4.7) eneity makes comparisons difficult
Finnish interventional	LOCS II	All opacity:	13 (-2, 28)
radiologists (Mrena <i>et al Scand J Work</i> Env Health 37 :237-43; 2011)		Problems with dos	imetry in certain cohorts



Non-cancer mortality disease in Abomb survivors (Ozasa et al. Radiat. Res. 177:229-43;2012)

All solid cancer	0.47 (0.38, 0.56)
All non-cancer	0.13 (0.08, 0.18)
Other diseases	0.03 (-0.11, 0.19)
Infectious disease	-0.03 (-0.22, 0.23)
Genitourinary disease	0.18 (-0.06, 0.46)
-Cirrhosis	0.11 (-0.07, 0.34)
Digestive disease	0.20 (0.05, 0.38)
Respiratory disease	0.23 (0.11, 0.36)
Circulatory disease	0.11 (0.05, 0.18)
Endpoint	ERR /Sv (95% CI)

Evidence of excess respiratory and digestive disease (+CVD)

Not seen in any other cohort (uniformity implying possible bias?)

But relative risk distinctly lower than for solid cancer (implying OK? Or due to death certificate misclassification of cancer as non-cancer?)



A-bomb survivor cause of death misclassification (Sposto et al Biometrics 48:605-17;1992)

- Increase in non-cancer mortality due to death certificate misclassification?
- Autopsy study finds 22% of non-cancer deaths misclassified as cancer deaths.
- Statistical adjustment reduces the ERR/Gy for non-cancer mortality from 0.06 to 0.05, but risk coefficient remains statistically significant.



Central nervous system effects

Many studies of childhood cancer survivors (principally of leukemia) document cognitive impairment associated with high dose cranial irradiation

Hall *et al.* (*Br. Med. J.* **328**:19;2004) suggested cognitive impairment in Swedish group treated for haemangioma in infancy with much lower doses, with ~50% reduction in high school attendance associated with >100 mGy; similar dose-related reductions in cognitive test performance

In utero exposed A-bomb data also suggest cognitive impairment at high dose (Schull & Otake *Teratology* **59**:222-6;1999), but no cognitive impairment (e.g., reduction in IQ) in 0-100 mGy dose range Are low dose studies (A-bomb, Hall *et al.*) consistent (metrics differ)? Is *in utero* same as early childhood?



Conclusions

Circulatory disease

- Meta-analysis of moderate+low-dose data suggests significant excess risk for two out of four circulatory disease endpoints (ischaemic heart, stroke), and aggregate risk significant
- Risk factors from moderate+low-dose cohorts suggest radiation-associated population risks of circulatory disease are similar to radiation-induced cancer
- Apart from A-bomb + Mayak, few cohorts have information on major lifestyle factors (smoking, drinking, obesity, HDL+LDL cholesterol, hypertension, diabetes), but little indication that these confound in A-bomb or Mayak

Cataract

- Evidence that cortical + posterior subcapsular cataract are radiation induced, but not nuclear
- Thresholds of >0.6 Gy can be ruled out for cataract (but lin/LQ increase with dose?)

Other non-malignant

- Significant excess of non-malignant respiratory and digestive disease mortality in Abomb data, but not seen in any other exposed group (probably not misclassification?)
- Possibly inconsistent evidence for neuro-cognitive effects after exposure *in utero*, early childhood